CROI 2024: Opening lecture calls for scientists to speak up for LGBTQ+ rights in Uganda
24 March 2024. Related: Conference reports, Treatment access, Women's health, Pregnancy, Vaccines and microbicides.
Pregnancy
IAS 2023: Bictegravir use in pregnancy: more data needed
1 October 2023. Related: Conference reports, Pregnancy.
IAS 2023: In-utero tenofovir-based PrEP has no effect on children’s bone mineral density
1 October 2023. Related: Conference reports, Pregnancy, Paediatric care, HIV prevention and transmission.
No vertical HIV transmissions in the UK from women eligible for supported breastfeeding
1 August 2023. Related: Conference reports, Pregnancy, Paediatric care.
Adverse birth outcomes with diabetes and hypertensive disorders in pregnancy
1 August 2023. Related: Conference reports, Pregnancy.
Implications of restrictions on reproductive rights for HIV care in the USA and beyond
6 April 2023. Related: Conference reports, Treatment access, Women's health, Pregnancy.
CROI 2023: Point-of-care testing for mothers and infants: results from the LIFE study
10 March 2023. Related: Conference reports, Pregnancy, Paediatric care.
Zero transmission in France for mothers on ART from conception with undetectable viral load at delivery
1 February 2023. Related: Pregnancy.
Glasgow 2022: Vertical transmission rate below 0.3% among women living with HIV in the UK
1 December 2022. Related: Conference reports, Pregnancy.
Dolutegravir no longer linked to higher risk of neural tube defects: latest update from the Tsepamo study
1 September 2022. Related: Conference reports, Pregnancy.
Using PrEP during pregnancy is safe for children
1 September 2022. Related: Conference reports, Pregnancy, Paediatric care.
CROI 2022: Higher maternal mortality and adverse birth outcomes among women with COVID-19 in Botswana
1 March 2022. Related: Conference reports, Women's health, Pregnancy.
Few vertical HIV transmissions in the UK but contributing factors remain associated with inequality
1 July 2021. Related: Conference reports, Pregnancy.
No differences in outcomes among women with and without HIV with high-risk pregnancies and COVID-19
1 June 2021. Related: Conference reports, Pregnancy, COVID-19: pathogenesis, COVID-19.
Dolutegravir-based regimens safe and effective in pregnancy and postpartum
1 June 2021. Related: Conference reports, Pregnancy.
CROI 2021: Pregnancy outcomes and weight gain with dolutegravir and TAF
1 April 2021. Related: Conference reports, Pregnancy.
Promising data for multipurpose technologies to prevent HIV and pregnancy
24 February 2021. Related: Conference reports, Pregnancy, HIV prevention and transmission.
Adverse pregnancy outcomes among Spanish women hospitalised with COVID-19
11 November 2020. Related: Conference reports, Pregnancy, COVID-19: transmission & prevention, COVID-19.
No increase in adverse birth outcomes with IPT-exposure in pregnancy in two African cohorts
11 November 2020. Related: Conference reports, Pregnancy, TB coinfection.
Neural tube defects in two of 1000 conception exposures with dolutegravir: reassuring update from Tsepamo study
22 July 2020. Related: Conference reports, Pregnancy.
Obesity linked to dolutegravir, especially with TAF, could increase risk of adverse pregnancy outcomes
22 July 2020. Related: Conference reports, Women's health, Pregnancy, Side effects.
Pregnancy meta-analysis: dolutegravir- versus efavirenz-based ART
22 July 2020. Related: Conference reports, Pregnancy.
Dolutegravir-based ART is safe and effective for pregnant women: first results from the VESTED trial
17 April 2020. Related: Conference reports, Pregnancy.
Postpartum weight gain is higher with dolutegravir- compared with efavirenz-based ART among African women
12 March 2020. Related: Conference reports, Pregnancy, Side effects.
Antiretroviral pregnancy registry: dolutegravir update
24 February 2020. Related: Conference reports, Pregnancy.
Bictegravir/emtricitabine/tenofovir alafenamide appears to be safe and effective in women: results from a pooled analysis
24 February 2020. Related: Conference reports, Pregnancy.
No link between raltegravir and adverse birth outcomes in analysis in 2550 women
18 October 2019. Related: Conference reports, Pregnancy.
Low rates of pregnancy with three methods of contraception in the ECHO trial
30 September 2019. Related: Conference reports, Pregnancy.
Other pregnancy studies IAS 2019
17 September 2019. Related: Conference reports, Pregnancy.
Dolutegravir neural tube defect risk declines but still slightly higher than with other antiretrovirals
24 July 2019. Related: Conference reports, Pregnancy.
High rates of viral suppression with low dose efavirenz in pregnant Zambian women
24 July 2019. Related: Conference reports, Pregnancy.
Infant dolutegravir exposure through placental and breastmilk transfer
19 June 2019. Related: Conference reports, Pregnancy, PK and drug interactions.
Antiretroviral pharmacokinetics in pregnancy: update from IMPAACT P1026s
19 June 2019. Related: Conference reports, Women's health, Pregnancy, TB coinfection.
No increased adverse outcomes among women starting dolutegravir before conception in the ADVANCE study
20 May 2019. Related: Conference reports, Pregnancy.
Integrase inhibitors and neural tube defects: more data still needed
28 March 2019. Related: Conference reports, Pregnancy.
Dear Doctor letter: Increased risk of treatment failure and increased risk of mother-to-child transmission of HIV infection dues to lower exposure of elvitegravir and cobicistat during the second and third trimesters of pregnancy
28 March 2019. Related: Pregnancy.
Dolutegravir suppresses viral load faster than efavirenz in late pregnancy: results from DolPHIN-2
12 March 2019. Related: Conference reports, Pregnancy.
Raltegravir achieves swifter viral load suppression in pregnancy than efavirenz
12 March 2019. Related: Conference reports, Pregnancy.
Hepatitis C is an independent risk factor for preterm delivery in HIV positive women: data from a Warsaw cohort
12 December 2018. Related: Conference reports, Pregnancy.
Vertical transmission remains very low in UK and Ireland: update from the National Study of HIV in Pregnancy and Childhood
12 December 2018. Related: Conference reports, Pregnancy.
No additional neural tube defects with preconception dolutegravir: data from three birth outcome cohorts
13 November 2018. Related: Conference reports, Pregnancy, Paediatric care.
Insufficient data on risk of neural tube defects with exposure to elvitegravir or bictegravir exposure during preconception or first trimester
13 November 2018. Related: Conference reports, Pregnancy.
TAF exposures during pregnancy and postpartum appear adequate but more data are needed
19 September 2018. Related: Conference reports, Pregnancy.
High rate of unintended pregnancy among HIV positive African women on ART
19 September 2018. Related: Conference reports, Women's health, Pregnancy.
WHO recommends dolutegravir widely but women’s access will depend on contraception provision (2018)
3 August 2018. Related: Conference reports, Women's health, Pregnancy, Guidelines.
No additional neural tube defects among a further 170 preconception dolutegravir exposures in Botswana: Tsepamo study (July 2018)
3 August 2018. Related: Conference reports, Pregnancy.
Swifter viral load suppression with dolutegravir vs efavirenz in late pregnancy: results from DolPHIN-1
3 August 2018. Related: Conference reports, Pregnancy.
Preconception safety signal with dolutegravir: data from the Tsepamo study
3 August 2018. Related: Conference reports, Pregnancy.
Dolutegravir preconception signal: time is up for shoddy surveillance
11 July 2018. Related: Special reports, Pregnancy.
Dolutegravir: need to consider all pros and cons before switching in pregnancy
11 July 2018. Related: Women's health, Pregnancy.
Why U=U does not apply to breastfeeding
11 July 2018. Related: Pregnancy, HIV prevention and transmission.
Janssen Dear Doctor letter: Prezista (darunavir), Rezolsta ▼(darunavir/cobicistat)and Symtuza ▼(darunavir/cobicistat/emtricitabine/tenofovir alafenamide)
29 June 2018. Related: Treatment alerts, Pregnancy.
Unbound dolutegravir plasma concentrations unchanged in pregnancy and standard dosing crosses the placenta in placental perfusion model
29 June 2018. Related: Conference reports, Pregnancy, PK and drug interactions.
Reduced exposure to elvitegravir in pregnancy: results from the PANNA Network
29 June 2018. Related: Conference reports, Pregnancy, PK and drug interactions.
BHIVA statement on potential safety signal in infants born to women conceiving on dolutegravir
8 June 2018. Related: Treatment alerts, Pregnancy, Side effects.
ViiV Dear Doctor letter: Neural tube defects reported in infants born to women exposed to dolutegravir at the time of conception
8 June 2018. Related: Treatment alerts, Pregnancy.
Potential safety signal for dolutegravir from the time of conception
21 May 2018. Related: Treatment alerts, Pregnancy.
Dolutegravir in pregnancy: early data reassuring but ongoing surveillance is still essential
21 May 2018. Related: Pregnancy.
Almost 1 in 8 people with symptoms turned away from sexual health clinics in SE London: 40% are under 25 and 6% under 18 years old
1 May 2018. Related: Conference reports, Treatment access, Women's health, Pregnancy, HIV prevention and transmission.
Key changes to upcoming UK HIV pregnancy guidelines (2018)
1 May 2018. Related: Conference reports, Pregnancy, Guidelines.
Pregnancy studies at 4th Joint BHIVA/BASHH Conference
1 May 2018. Related: Conference reports, Pregnancy.
Isoniazid preventive TB therapy in pregnancy and postpartum: recommendations now need to be re-evaluated
16 April 2018. Related: Conference reports, Women's health, Pregnancy, TB coinfection.
Efavirenz might decrease effectiveness of the vaginal contraceptive ring
16 April 2018. Related: Conference reports, Pregnancy, PK and drug interactions.
Standard dose of dolutegravir sufficient in late pregnancy: interim results from DolPHIN-1 study
30 March 2018. Related: Conference reports, Pregnancy.
Standard once-daily dolutegravir dosing achieves target levels during pregnancy
23 February 2018. Related: Pregnancy.